UNIVERSIDAD RICARDO PALMA FACULTAD DE MEDICINA HUMANA V CURSO INTERNACIONAL DE ACTUALIZACIÓN EN MEDICINA Y CIRUGIA – IV JO...
SHOCK CARDIOGENICO <ul><li>DEFINICION: </li></ul><ul><ul><li>EVIDENCIA CLINICA DE HIPOPERFUSION </li></ul></ul><ul><ul><li...
SHOCK CARDIOGENICO *   SIGUE SIENDO LA 1ª CAUSA DE MUERTE – IH – EN EL IMA (TAMI) I TRIAL  CIRCULATION 1988; 77: 1090-90 N...
SHOCK CARDIOGENICO <ul><li>CAUSAS </li></ul><ul><ul><li>EXTENSION DEL IMA (40% VI) </li></ul></ul><ul><ul><li>IMA DE VENTR...
SHOCK CARDIOGENICO <ul><li>PRIMER RX </li></ul><ul><ul><li>LIMITAR TAMAÑO DEL IMA </li></ul></ul><ul><ul><li>RESTABLECER R...
SHOCK CARDIOGENICO CURVAS DE PRESION Y DE PERFUSION CORONARIA
SHOCK CARDIOGENICO IMA <ul><li>Injuria Miocardica Irreversible  15 - 20 min </li></ul><ul><li>Injuria completa area de rie...
Emergency Management of Complicated STEMI <ul><li>Administer </li></ul><ul><li>Fluids </li></ul><ul><li>Blood transfusions...
All-Cause Mortality Years Probability of Event ACE-I 2995 2250 1617 892 223 Placebo 2971 2184 1521 853 138 Flather MD, et ...
Nitrates should not be administered to patients with: Nitrates should not be administered to patients who have received a ...
EVIDENCE GRADING A B C BENEFICIAL  HARMFUL RANDOMIZED  EXPERT OPINION SHOCK CARDIOGENICO IMA
Cardiogenic Shock 1-2 vessel CAD Moderate 3-vessel CAD Severe 3-vessel CAD Left main CAD PCI IRA PCI IRA Immediate CABG St...
SHOCK CARDIOGENICO <ul><li>< 75 AÑOS </li></ul><ul><ul><li>ST  </li></ul></ul><ul><ul><li>BCRI </li></ul></ul><ul><ul><li>...
SHOCK CARDIOGENICO <ul><li>STEMI + PAS < 90 mm Hg </li></ul><ul><li>PAm < 30 mm Hg  </li></ul>CLASE IB BALON INTRAORTICO D...
SHOCK CARDIOGENICO <ul><li>STEMI + TAQUICARDIA VENTRICULAR  POLIMORFA </li></ul>CLASE II a BALON INTARORTICO DE CONTRAPULS...
A C P
ACP PRIMARIA O DE RESCATE EN STEMI: <ul><li>DEBE REALIZARSE  –IB-  </li></ul><ul><li>en pacientes  severa (ICC)  (Killip c...
  APC POSTERIOR A FIBRINOLISIS APC debe ser realizada en  pacientes con:   Evidencia objetiva de   IMA recurrente Isquemia...
FIBRINOLÍSIS REPERFUSIÓN
SHOCK CARDIOGENICO <ul><li>FIBRINOLISIS </li></ul><ul><ul><li>CUANDO INTERVENCION ESTA CONTRAINDICADA </li></ul></ul><ul><...
SHOCK CARDIOGENICO THE SHOCK TRIAL (P=0.11) (P<0.03) REVASCULARIZACION 66.4% 53.3% 6 A 12 MESES 50.0% 46.7% MORTALIDAD 30 ...
SHOCK CARDIOGENICO <ul><li>CATETER PULMONAR </li></ul><ul><li>REVASCULARIZACION TEMPRANA </li></ul><ul><ul><li>< 75 AÑOS <...
Evidence-Based Approach to Need for  Catheterization and Revascularization After STEMI STEMI Primary Invasive Strategy Fib...
Right Ventricular Infarction Clinical findings: Shock with clear lungs, elevated JVP Kussmaul sign Hemodynamics:  Increase...
SHOCK CARDIOGENICO <ul><li>EKG  + V4R </li></ul><ul><li>ECOCARDIOGRAMA  </li></ul>CLASE I SOSPECHA DE IMA VD  STEMI + INES...
Ventricular Septal Rupture Mitral Regurgitation (Pap. M. dysfunction) Incidence 1-2%   1-6% 1-2% Timing 3-5 d p MI   3-6 d...
SHOCK CARDIOGENICO <ul><li>RUPTURA DE MUSCULO PAPILAR </li></ul><ul><ul><ul><li>CIRUGIA URGENTE </li></ul></ul></ul>REGURG...
SHOCK CARDIOGENICO <ul><li>CIRUGIA URGENTE </li></ul>RUPTURA SEPTAL O DE PARED LIBRE <ul><li>CABG </li></ul>Ventricular Se...
SHOCK CARDIOGENICO <ul><li>STEMI + AV + ARRITMIA INTRATABLE Y/O SHOCK </li></ul><ul><ul><ul><li>ANEURISMECTOMIA + CABC </l...
ICD Implantation After STEMI One Month After STEMI;  No Spontaneous VT or VF 48 hours post-STEMI EF < 0.30 EPS Yes + NEJM ...
<ul><li>Atacado de fiebres un indio de Loja llamado Pedro de Leyva, bebió, para calmar los ardores de la sed, del agua de ...
PAZ MUNDIAL
Upcoming SlideShare
Loading in …5
×

S H O C K C A R I O G E N I C O2

2,043 views

Published on

0 Comments
3 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
2,043
On SlideShare
0
From Embeds
0
Number of Embeds
6
Actions
Shares
0
Downloads
84
Comments
0
Likes
3
Embeds 0
No embeds

No notes for slide
  • EL PRIMER PASO AL MANEJO DE SHOCK CARDIOGENO ES SU PREVENCIÓN MEDIANTE LA LIMITACIÓN DEL TAMAÑO DEL IMA, RESTABLECER LA PERFUSIÓN CORONARIA Y CONTROLANDO LAS RESPUESTAS INJURIOSAS
  • La perfusión coronaria ocurre el momento de máximo volumen de VI y de mínima resistencia del mismo. Las 2 Presiones coronarias y --- generan perfusión contra la baja resistencia Diastólica En sistole las presiones de A– y VI se igualan el VI se contrae no hay perfusión + volumen VI. Si la presión coronaria cae bajo la Presión aórtica, el flujo se mantiene por auto refulación. ------ Luego ISQUEMIA = ------ CONTRACTILIDAD PFVI Bajo Gas—o SHOCK P P ISQUEMIA
  • The emergency management of patients with cardiogenic shock (CS), acute pulmonary edema (PE) or both is outlined. Las complicaciones que demandan emergencias ee el IMA mas comunmente son Edema Pulmonar Agudo, Hipovolemia, Shoc Cadiógeno y Arritmias: Si la PAS está 70 a 100 mm Hg, Pero sin Sx ni Sg de ShocK: Dobutamina 2 a 20 mcg/kg/min IV. Si la PAS esta &lt;70 a 100 mm Hg con Sx y Sx de Shock: Dopamine 5 a 18 mcg/Kg/min IV Si la PAS esta &lt;70 mm Hg: Norepinefrina 5 a 30 mcg/Kg/min IV. Si la PAS &gt;100mm Hg: NTG. Si la PAS &gt;100 mmHg ( y hasta 30 mmhg de la PA basal): Inhibidores e la ECA. El siguiente paso medidas DX y RX
  • Desde e Etudio SOLVD con el Enalapril se ha prbado que los inhibidores de la ECA mejoran mortalidad en presencia de bajo gasto o ICC. Lo confirman el SAVE, el AIRE, el TRACE.
  • Seguimos el mismo abordaje Probabilístico de 4 CLASES de INDICACIONES de lo Beneficioso a lo Perjudicial con 3 niveles de Evidencia.
  • Pacientes e Shock Cardíogenico de Presentación Temprana o TARDIA ------ IABP ---- ANYLA ---- REN---LIZA Ahora, en la Presentación Temprana ----- FIBRINOLISIS, si es que &gt;90¨ ( sin APC ) &lt; 3 HORAS del IMA 1 – 2 Vasos 3 vasos Modea--- 3 vasos o tienen A P C ARI Otros Vasos
  • This algorithm shows the treatment paths for patients who initially undergo a primary invasive strategy, receive fibrinolytic therapy, or do not undergo reperfusion therapy for STEMI. Patients who have not undergone a primary invasive strategy and have no high risk features should undergo functional evaluation using one of the noninvasive tests shown. When clinically significant ischemia is detected, patients should undergo catheterization and revascularization as indicated; if no clinically significant ischemia is detected, medical therapy is prescribed post-STEMI.
  • Algorithm to aid in selection of implantable cardioverter/defibrillator (ICD) in patients with STEMI and diminished ejection fraction (EF). The appropriate management path is selected based upon left ventricular ejection fraction (LVEF) measured at least one month after STEMI. These criteria, that are based on the published data, form the basis for the full-text guidelines in section 7.7.1.5. All patients, whether an ICD is implanted or not, should receive medical therapy as outlined in the full-text guidelines.
  • S H O C K C A R I O G E N I C O2

    1. 1. UNIVERSIDAD RICARDO PALMA FACULTAD DE MEDICINA HUMANA V CURSO INTERNACIONAL DE ACTUALIZACIÓN EN MEDICINA Y CIRUGIA – IV JORNADA DE EDUCACIÓN MÉDICA UNIVERSITARIA CONFERENCIA: “ SHOCK CARDIOGÉNICO” DOCTOR ALFREDO PALACIO I N C A P U E E S INSTITUTO NACIONAL DE CARDIOLOGIA FACULTAD DE MEDICINA “ ALFREDO PALACIO” “ENRIQUE ORTEGA MOREIRA” GUAYAQUIL – ECUADOR
    2. 2. SHOCK CARDIOGENICO <ul><li>DEFINICION: </li></ul><ul><ul><li>EVIDENCIA CLINICA DE HIPOPERFUSION </li></ul></ul><ul><ul><li>CON PRESION ARTERIAL SISTOLICA < 90 mm Hg > 30 min </li></ul></ul><ul><ul><li>NECESIDAD DE TERAPIA PARA MANTENER PAS > DE 90 mmHg </li></ul></ul><ul><ul><li>IC < 2.2 L/ min / m2 </li></ul></ul><ul><ul><li>PCP (en cuña) > 15 mm Hg </li></ul></ul>THE SHOCK TRIAL JAMA 2001; 285: 190-2
    3. 3. SHOCK CARDIOGENICO * SIGUE SIENDO LA 1ª CAUSA DE MUERTE – IH – EN EL IMA (TAMI) I TRIAL CIRCULATION 1988; 77: 1090-90 NEJM 1991; 325: 1117-22 JACC 1992; 20: 1982-9 20-50% 70 % + / IABP SOBREVIDA – IH - INTRAHOSPITALARIA 40% * 80% MORTALIDAD 5 – 7 % 20% PREVALENCIA EN IMA REPERFUSION PREREPERFUSION
    4. 4. SHOCK CARDIOGENICO <ul><li>CAUSAS </li></ul><ul><ul><li>EXTENSION DEL IMA (40% VI) </li></ul></ul><ul><ul><li>IMA DE VENTRICULO DERECHO </li></ul></ul><ul><ul><li>RM AGUDA (RUPTURA DE MP) </li></ul></ul><ul><ul><li>CIV AGUDA </li></ul></ul><ul><ul><li>RUPTURA DE PARED LIBRE </li></ul></ul><ul><ul><li>TAPONAMIENTO CARDIACO </li></ul></ul>
    5. 5. SHOCK CARDIOGENICO <ul><li>PRIMER RX </li></ul><ul><ul><li>LIMITAR TAMAÑO DEL IMA </li></ul></ul><ul><ul><li>RESTABLECER REPERFUSION CORONARIA </li></ul></ul><ul><ul><li>CONTROLAR RESPUESTAS INJURIOSAS </li></ul></ul><ul><ul><ul><ul><ul><li>ACTIVIDAD SIMPATICA </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>SISTEMA SRA </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>RESISTENCIA PERIFERICA </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>POST CARGA </li></ul></ul></ul></ul></ul>
    6. 6. SHOCK CARDIOGENICO CURVAS DE PRESION Y DE PERFUSION CORONARIA
    7. 7. SHOCK CARDIOGENICO IMA <ul><li>Injuria Miocardica Irreversible 15 - 20 min </li></ul><ul><li>Injuria completa area de riesgo 4 - 6 Hrs </li></ul><ul><li>Mayor magnitud del daño 2 - 3 Hrs </li></ul><ul><li>Restauración del flujo para </li></ul><ul><li>obtener mayor beneficio 1 - 2 Hrs </li></ul><ul><li>Hipóteis de arteria abierta </li></ul><ul><li>flujo normal mortalidad </li></ul><ul><li>Tamaño de infarto lo anterior mas colaterales </li></ul>
    8. 8. Emergency Management of Complicated STEMI <ul><li>Administer </li></ul><ul><li>Fluids </li></ul><ul><li>Blood transfusions </li></ul><ul><li>Cause-specific interventions </li></ul><ul><li>Consider vasopressors </li></ul>Arrhythmia Bradycardia Tachycardia Systolic BP Greater than 100 mm Hg Systolic BP 70 to 100 mm Hg NO signs/symptoms of shock Systolic BP 70 to 100 mm Hg Signs/symptoms of shock Systolic BP l ess than 70 mm Hg Signs/symptoms of shock Dobutamine 2 to 20 mcg/kg per minute IV Low Output - Cardiogenic Shock Nitroglycerin 10 to 20 mcg/min IV Dopamine 5 to 15 mcg/kg per minute IV Norepinephrine 0.5 to 30 mc g/min IV Hypovolemia <ul><li>Administer </li></ul><ul><li>Furosemide IV 0.5 to 1.0 mg/kg </li></ul><ul><li>Morphine IV 2 to 4 mg </li></ul><ul><li>Oxygen /intubation as needed </li></ul><ul><li>Nitroglycerin SL, then 10 to 20 mcg/min IV if SBP greater than 100 mm Hg </li></ul><ul><li>Dopamine 5 to 15 mcg/kg per minute IV if SBP 70 to 100 mm Hg and signs/symptoms of shock present </li></ul><ul><li>Dobutamine 2 to 20 mcg/kg per minute IV if SBP 70 to 100 mm Hg and no signs/symptoms of shock </li></ul>First line of action Second line of action Third line of action ACC/AHA Guidelines for Patients With ST-Elevation Myocardial Infarction Check Blood Pressure Clinical signs: Shock, hypoperfusion, congestive heart failure, acute pulmonary edema Most likely major underlying disturbance? Further diagnostic/therapeutic considerations (should be considered in nonhypovolemic shock) Diagnostic Therapeutic ♥ Pulmonary artery catheter ♥ Intra-aortic balloon pump ♥ Echocardiography ♥ Reperfusion/revascularization ♥ Angiography for MI/ischemia ♥ Additional diagnostic studies Acute Pulmonary Edema Check Blood Pressure Systolic BP Greater than 100 mm Hg and not less than 30 mm Hg below baseline ACE Inhibitors Short-acting agent such as captopril (1 to 6.25 mg) Circulation 2000;102(suppl I):I-172-I-216.
    9. 9. All-Cause Mortality Years Probability of Event ACE-I 2995 2250 1617 892 223 Placebo 2971 2184 1521 853 138 Flather MD, et al. Lancet . 2000;355:1575–1581 OR: 0.74 (0.66–0.83) ACE-I: 702/2995 (23.4%) Placebo: 866/2971 (29.1%) TRACE Echocardiographic EF  35% AIRE Clinical and/or radiographic signs of HF SAVE Radionuclide EF  40% 0 0.05 0.1 0.15 0.2 0.25 0.3 0 1 2 3 0.35 0.4 4 ACE-I Placebo
    10. 10. Nitrates should not be administered to patients with: Nitrates should not be administered to patients who have received a phosphodiesterase inhibitor for erectile dysfunction within the last 24 hours (48 hours for tadalafil). <ul><li>systolic pressure < 90 mm Hg or ≥ to 30 mm Hg below baseline </li></ul><ul><li>severe bradycardia (< 50 bpm) </li></ul><ul><li>tachycardia (> 100 bpm) or </li></ul><ul><li>suspected RV infarction. </li></ul>When NOT to give Nitroglycerin SHOCK CARDIOGENICO IMA
    11. 11. EVIDENCE GRADING A B C BENEFICIAL HARMFUL RANDOMIZED EXPERT OPINION SHOCK CARDIOGENICO IMA
    12. 12. Cardiogenic Shock 1-2 vessel CAD Moderate 3-vessel CAD Severe 3-vessel CAD Left main CAD PCI IRA PCI IRA Immediate CABG Staged Multivessel PCI Staged CABG Cannot be performed Early Shock, Diagnosed on Hospital Presentation Delayed Onset Shock Echocardiogram to Rule Out Mechanical Defects Cardiac Catheterization and Coronary Angiography IABP Fibrinolytic therapy if all of the following are present: 1. Greater than 90 minutes to PCI 2. Less than 3 hours post STEMI onset 3. No contraindications Arrange prompt transfer to invasive procedure-capable center Arrange rapid transfer to invasive procedure-capable center PCI for Cardiogenic Shock
    13. 13. SHOCK CARDIOGENICO <ul><li>< 75 AÑOS </li></ul><ul><ul><li>ST </li></ul></ul><ul><ul><li>BCRI </li></ul></ul><ul><ul><li>SHOCK < 36 HS DEL IMA </li></ul></ul><ul><ul><li>INTERVENCION < 18 HORAS </li></ul></ul><ul><ul><li>REVASCULARIZACION TEMPRANA </li></ul></ul>CLASE IA <ul><ul><ul><ul><ul><li>BALON DE CONTRAPULSACION AORTICO (IABP) </li></ul></ul></ul></ul></ul>I I I IIa IIa IIa IIb IIb IIb III III III I I I IIa IIa IIa IIb IIb IIb III III III I I I IIa IIa IIa IIb IIb IIb III III III IIa IIa IIa IIb IIb IIb III III III A
    14. 14. SHOCK CARDIOGENICO <ul><li>STEMI + PAS < 90 mm Hg </li></ul><ul><li>PAm < 30 mm Hg </li></ul>CLASE IB BALON INTRAORTICO DE CONTRAPULSACION (IABP) <ul><li>STEMI + ESTADO DE BAJO GASTO CARDIACO </li></ul><ul><li>STEMI + SHOCK SIN RESPUESTA FARMACOLOGICA </li></ul><ul><li>STEMI + DOLOR PRECORDIAL </li></ul><ul><li> ISQUEMIA RECURRENTE </li></ul><ul><li> INESTABILIDAD HEMODINAMICA </li></ul><ul><li> FUNCION VENTRICULAR DEPRIMIDA </li></ul><ul><li> AREA MIOCARDICA DE RIESGO GRANDE </li></ul><ul><li>IACB + CAT + CIRUGIA </li></ul>CLASE IC I I I IIa IIa IIa IIb IIb IIb III III III I I I IIa IIa IIa IIb IIb IIb III III III I I I IIa IIa IIa IIb IIb IIb III III III IIa IIa IIa IIb IIb IIb III III III B
    15. 15. SHOCK CARDIOGENICO <ul><li>STEMI + TAQUICARDIA VENTRICULAR POLIMORFA </li></ul>CLASE II a BALON INTARORTICO DE CONTRAPULSACION (IABP) <ul><li>STEMI + ICC </li></ul>
    16. 16. A C P
    17. 17. ACP PRIMARIA O DE RESCATE EN STEMI: <ul><li>DEBE REALIZARSE –IB- </li></ul><ul><li>en pacientes severa (ICC) (Killip clase 3) </li></ul><ul><li>con Sx < 12 horas </li></ul><ul><li>La ACP Primaria debe realizarse -IA- </li></ul><ul><li>en pacientes < 75 años </li></ul><ul><li>con elevación ST o BCRI </li></ul><ul><li>SHOCK <36 horas post MI, </li></ul><ul><li>ACP realizable <primeras 18 horas del shock. </li></ul><ul><li>En pacientes >75 años: - IIa B- </li></ul>SHOCK CARDIOGENICO IMA
    18. 18. APC POSTERIOR A FIBRINOLISIS APC debe ser realizada en pacientes con: Evidencia objetiva de IMA recurrente Isquemia miocardica moderada o severa , ya sea espontanea o provocada , durante la recuperacion STEMI Shock cardiogenico o inestabilidad hemodinamica . SHOCK CARDIOGENICO IMA
    19. 19. FIBRINOLÍSIS REPERFUSIÓN
    20. 20. SHOCK CARDIOGENICO <ul><li>FIBRINOLISIS </li></ul><ul><ul><li>CUANDO INTERVENCION ESTA CONTRAINDICADA </li></ul></ul><ul><li>MONITOREO HEMODINAMICO INTRAARTERIAL </li></ul><ul><li>ECOCARDIOGRAFIA </li></ul><ul><ul><li>(EVIDENCIAR COMPLICACIONES MECANICAS) </li></ul></ul>CLASE I I I I IIa IIa IIa IIb IIb IIb III III III I I I IIa IIa IIa IIb IIb IIb III III III I I I IIa IIa IIa IIb IIb IIb III III III IIa IIa IIa IIb IIb IIb III III III B
    21. 21. SHOCK CARDIOGENICO THE SHOCK TRIAL (P=0.11) (P<0.03) REVASCULARIZACION 66.4% 53.3% 6 A 12 MESES 50.0% 46.7% MORTALIDAD 30 DIAS ESTABILIZACION MEDICA INICAL REVASCULARIZACION DE EMERGENCIA
    22. 22. SHOCK CARDIOGENICO <ul><li>CATETER PULMONAR </li></ul><ul><li>REVASCULARIZACION TEMPRANA </li></ul><ul><ul><li>< 75 AÑOS </li></ul></ul><ul><ul><li>ST </li></ul></ul><ul><ul><li>BCRI </li></ul></ul><ul><ul><li>SHOCK < 36 HS DEL IMA </li></ul></ul><ul><ul><li>INTERVENCION < 18 HORAS </li></ul></ul><ul><ul><li>> 75 AÑOS INDICACION IIaB </li></ul></ul>CLASE II I I I IIa IIa IIa IIb IIb IIb III III III I I I IIa IIa IIa IIb IIb IIb III III III I I I IIa IIa IIa IIb IIb IIb III III III IIa IIa IIa IIb IIb IIb III III III A
    23. 23. Evidence-Based Approach to Need for Catheterization and Revascularization After STEMI STEMI Primary Invasive Strategy Fibrinolytic Therapy No Reperfusion Therapy Cath Performed No Cath Performed EF greater than 0.40 EF less than 0.40 EF less than 0.40 EF greater than 0.40 High - Risk Features † No High - Risk Features † No High - Risk Features † High - Risk Features † Functional Evaluation ECG Interpretable ECG Uninterpretable Able to Exercise Unable to Exercise Submaximal Exercise Test Before Discharge Symptom - Limited Exercise Test Before or After Discharge Pharmacological Stress Nuclear Scan Dobutamine Echo Clinically Significant Ischemia* No Clinically Significant Ischemia* Medical Therapy Revascularization as Indicated Catheterization and Revascularization as Indicated Catheterization and Revascularization as Indicated Able to Exercise Exercise Echo Exercise Nuclear STEMI Primary Invasive Strategy Fibrinolytic Therapy No Reperfusion Therapy Cath Performed No Cath Performed EF greater than 0.40 EF less than 0.40 EF less than 0.40 EF greater than 0.40 High - Risk Features No High - Risk Features No High - Risk Features High - Risk Features Functional Evaluation ECG Interpretable ECG Uninterpretable Able to Exercise Unable to Exercise Submaximal Exercise Test Before Discharge Symptom - Limited Exercise Test Before or After Discharge Pharmacological Stress Adenosine or Dipyridamole Dobutamine Echo Clinically Significant Ischemia No Clinically Significant Ischemia Medical Therapy Revascularization as Indicated Catheterization and Revascularization as Indicated Catheterization and Revascularization as Indicated Able to Exercise Exercise Echo Exercise Nuclear
    24. 24. Right Ventricular Infarction Clinical findings: Shock with clear lungs, elevated JVP Kussmaul sign Hemodynamics: Increased RA pressure (y descent) Square root sign in RV tracing ECG: ST elevation in R sided leads Echo: Depressed RV function Rx: Maintain RV preload Lower RV afterload (PA---PCW) Inotropic support Reperfusion V 4 R Modified from Wellens. N Engl J Med 1999;340:381.
    25. 25. SHOCK CARDIOGENICO <ul><li>EKG + V4R </li></ul><ul><li>ECOCARDIOGRAMA </li></ul>CLASE I SOSPECHA DE IMA VD STEMI + INESTABILIDAD HEMODINAMICA INFERIOR <ul><li>REPERFUSION TEMPRANA ACP </li></ul><ul><li>CORREGIR BRADICARDIA Y ASINCRONIA AV </li></ul><ul><li>PRECARGA DERECHA </li></ul><ul><ul><li>CARGA INICAL RESPUESTA POSITIVA </li></ul></ul><ul><ul><li>OPTIMIZAR VOLUMEN </li></ul></ul><ul><ul><li>PV < NORMAL </li></ul></ul><ul><li>POSCARGA DERECHA </li></ul><ul><li>OPTIMIZAR FUNCION V IZQ. </li></ul><ul><li>ASISTENCIA INOTROPICA </li></ul><ul><ul><li>CUANDO SOBRECARGA DE VOLUMEN ES INSUFICIENTE </li></ul></ul>I I I IIa IIa IIa IIb IIb IIb III III III I I I IIa IIa IIa IIb IIb IIb III III III I I I IIa IIa IIa IIb IIb IIb III III III IIa IIa IIa IIb IIb IIb III III III B
    26. 26. Ventricular Septal Rupture Mitral Regurgitation (Pap. M. dysfunction) Incidence 1-2% 1-6% 1-2% Timing 3-5 d p MI 3-6 d p MI 3-5 d p MI Phy Exam murmur 90% JVD, EMD murmur 50% Thrill Common No Rare Echo Shunt Peric. Effusion Regurg. Jet PA cath O 2 step up Diast Press Equal. c-v wave in PCW Images:Courtesy of W D Edwards (Mayo Foundation) Data: Lavocitz. CV Rev Rpt 1984;5:948; Birnbaum. NEJM 2002;347:1426. Free Wall Rupture
    27. 27. SHOCK CARDIOGENICO <ul><li>RUPTURA DE MUSCULO PAPILAR </li></ul><ul><ul><ul><li>CIRUGIA URGENTE </li></ul></ul></ul>REGURGITACION MITRAL <ul><li>CONCOMITANTE CABG </li></ul>Mitral Regurgitation (Pap. M. dysfunction) I I I IIa IIa IIa IIb IIb IIb III III III I I I IIa IIa IIa IIb IIb IIb III III III I I I IIa IIa IIa IIb IIb IIb III III III IIa IIa IIa IIb IIb IIb III III III B
    28. 28. SHOCK CARDIOGENICO <ul><li>CIRUGIA URGENTE </li></ul>RUPTURA SEPTAL O DE PARED LIBRE <ul><li>CABG </li></ul>Ventricular Septal Rupture I I I IIa IIa IIa IIb IIb IIb III III III I I I IIa IIa IIa IIb IIb IIb III III III I I I IIa IIa IIa IIb IIb IIb III III III IIa IIa IIa IIb IIb IIb III III III B
    29. 29. SHOCK CARDIOGENICO <ul><li>STEMI + AV + ARRITMIA INTRATABLE Y/O SHOCK </li></ul><ul><ul><ul><li>ANEURISMECTOMIA + CABC </li></ul></ul></ul>ANEURISMA VENTRICULAR I I I IIa IIa IIa IIb IIb IIb III III III I I I IIa IIa IIa IIb IIb IIb III III III I I I IIa IIa IIa IIb IIb IIb III III III IIa IIa IIa IIb IIb IIb III III III B
    30. 30. ICD Implantation After STEMI One Month After STEMI; No Spontaneous VT or VF 48 hours post-STEMI EF < 0.30 EPS Yes + NEJM 349: 1836,2003 EF 0.31 - 0.40 No EF > 0.40 - No ICD. Medical Rx Additional Marker of Electrical Instability?
    31. 31. <ul><li>Atacado de fiebres un indio de Loja llamado Pedro de Leyva, bebió, para calmar los ardores de la sed, del agua de un remanso, en cuyas orillas crecían algunos árboles de quina … Con su descubrimiento vino a Lima y lo comunicó a un jesuita, el que, realizando la feliz curación de la virreina, prestó a la Humanidad mayor servicio que el fraile que inventó la pólvora. </li></ul><ul><li>Mendiburo dice que, al principio, encontró el uso de la quina fuerte oposición en Europa, y que en Salamanca se sostuvo que caía en pecado mortal el médico que la recetaba, pues sus virtudes eran debidas a pacto de los peruanos con el diablo. </li></ul>
    32. 32. PAZ MUNDIAL

    ×